West Pharmaceutical shareholders reject independent board chair proposal at annual meeting

Filed May 5, 2026 · Period ending May 4, 2026 · ~1 min read

Key Changes

• medium

  Shareholders voted down a proposal requiring an independent board chair (46% for, 54% against), allowing current leadership structure to continue. This was the only contested item at the meeting.

  Item 5.07 verify on EDGAR →
• low

  All 11 director nominees elected to one-year terms with majority support, providing board continuity through 2027 annual meeting.

  Item 5.07 verify on EDGAR →
• low

  Executive compensation approved with 94% shareholder support (60.1M for vs 3.8M against), indicating satisfaction with pay practices.

  Item 5.07 verify on EDGAR →